- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02533544
Treatment Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in naïve Chronic Hepatitis B
Treatment Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in naïve Chronic Hepatitis B : a Real Life Multicenter Cohort Study in Korea
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Daejeon
-
Junggu, Daejeon, Korea, Republic of
- The Catholic University of Korea, Daejeon St.Mary's Hosptial
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.
- Adult male and non-pregnant, non-lactating female subjects, 19 years of age and older, based on the date of the screening visit. A negative serum pregnancy test at Screening is required for female subjects of childbearing potential (unless surgically sterile or greater than 2 years post-menopausal).
- Documented evidence of chronic HBV infection (e.g. HBsAg positive for more than 6 months)
Chronic hepatitis B with the following:
- HBeAg-positive and HBeAb negative at Screening
- Screening HBV DNA ≥ 1x 105 copies/mL
- Screening serum ALT level ≥ ×ULN(80 IU/L) and ≤ 10 ×ULN (by center laboratory range) OR
- HBeAg-negative and HBeAb positive at Screening
- Screening HBV DNA ≥ 1x 104 copies/mL
- Screening serum ALT level ≥ ×ULN(80 IU/L) and ≤ 10 ×ULN (by center laboratory range) OR
- Cirrhosis at Screening
- Screening HBV DNA ≥ 1x 104 copies/mL in HBeAg negative or
- Screening HBV DNA ≥ 1x 105 copies/mL in HBeAg positive
- Screening serum ALT level ≥ ×ULN and ≤ 10 ×ULN (by center laboratory range)
- A patient who treating with TDF as a treatment-naïve for Hepatitis B. Treatment naïve subjects defined as no history of antiviral therapy or < 12 weeks of oral antiviral treatment with any nucleoside or nucleotide analogue, including lamivudine or adefovir, clevudine, telbivudine, entecavir
- Decompensated liver cirrhosis defined based on a Child-Turcotte-Pugh (CTP) score ≥ 7 (Child B and C) or presence with at least one episode of ascites, jaundice, hepatic encephalopathy or variceal bleeding
- Any previous treatment with interferon (pegylated or non-pegylated) must have ended at least 6 months prior to the baseline visit
- Must be willing and able to comply with all study requirements.
Exclusion Criteria:
Subjects who meet any of the following exclusion criteria are not to be enrolled in the study.
- Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study.
- Co-infection with HCV, HIV
- Evidence of hepatocellular carcinoma (e.g. α-fetoprotein> 50 ng/mL or as evidenced by recent ultrasound or other standard of care measure)
- Malignancy within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (basal cell skin cancer, etc). Subjects under evaluation for possible malignancy are not eligible
- Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance
- Currently receiving therapy with cytotoxic agent, nephrotoxic agents, or agents capable of modifying renal excretion
- Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
tenofovir disoproxil fumarate monotherapy
a group which treated with tenofovir disoproxil fumarate
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of subjects with plasma HBV DNA levels below 116 copies/mL at Week 48
Time Frame: week 48
|
proportion of subjects with plasma HBV DNA levels below 116 copies/mL at Week 48
|
week 48
|
The proportion of subjects with plasma HBV DNA levels below 116 copies/mL at Week 96
Time Frame: Week 96
|
proportion of subjects with plasma HBV DNA levels below 116 copies/mL at Week 96
|
Week 96
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of subjects with plasma HBV DNA levels below 116 copies/mL at every visits
Time Frame: week 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144
|
The proportion of subjects with plasma HBV DNA levels below 116 copies/mL at every visits
|
week 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144
|
The proportion of the biochemical (alanine aminotransferase normalization) response of TDF for the treatment of chronic hepatitis B at Week 48 and 96
Time Frame: Week 48 and 96
|
The proportion of the biochemical (alanine aminotransferase normalization) response of TDF for the treatment of chronic hepatitis B at Week 48 and 96
|
Week 48 and 96
|
The proportion of the serological response (loss of HBeAg and seroconversion to HBeAb) of TDF for the treatment of chronic hepatitis B at Week 48 and 96
Time Frame: Week 48 and 96
|
The proportion of the serological response (loss of HBeAg and seroconversion to HBeAb) of TDF for the treatment of chronic hepatitis B at Week 48 and 96
|
Week 48 and 96
|
The proportion of the serological response (loss of HBsAg and seroconversion to HBsAb) of TDF for the treatment of chronic hepatitis B at Week 48 and 96
Time Frame: Week 48 and 96
|
The proportion of the serological response (loss of HBsAg and seroconversion to HBsAb) of TDF for the treatment of chronic hepatitis B at Week 48 and 96
|
Week 48 and 96
|
The change from baseline in the decline of HBV DNA at every visits
Time Frame: week 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144
|
The change from baseline in the decline of HBV DNA at every visits
|
week 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144
|
The proportion of patients showing virological breakthrough at week 48 and 96
Time Frame: Week 48 and 96
|
The proportion of patients showing virological breakthrough at week 48 and 96. Virological Breakthrough defined as any increase in serum HBV DNA by >1 log10 from nadir or redetection of serum HBV DNA at levels ≥10-fold the lower limit of detection of the HBV DNA assay after having an undetectable result |
Week 48 and 96
|
The incidence of resistance of TDF among patients showing virological breakthrough at week 48 and 96
Time Frame: Week 48 and 96
|
The incidence of resistance of TDF among patients showing virological breakthrough at week 48 and 96. Virological Breakthrough defined as any increase in serum HBV DNA by >1 log10 from nadir or redetection of serum HBV DNA at levels ≥10-fold the lower limit of detection of the HBV DNA assay after having an undetectable result |
Week 48 and 96
|
The proportion of improvement of liver function including Child Score, Model for End-stage Liver Disease (MELD) score at Week 48 and 96
Time Frame: Week 48 and 96
|
The proportion of improvement of liver function including Child Score, MELD score at Week 48 and 96
|
Week 48 and 96
|
The proportion of improvement of Fibrosis marker including Aspartate aminotransferase to Platelet Ratio Index(APRI) at Week 48 and 96
Time Frame: Week 48 and 96
|
The proportion of improvement of Fibrosis marker including Aspartate aminotransferase to Platelet Ratio Index(APRI) at Week 48 and 96
|
Week 48 and 96
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Myeong Jun Song, Ph.D. M.D., The Catholic University of Korea
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Tenofovir
Other Study ID Numbers
- IN-US-174-1805
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hepatitis B
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Tongji HospitalGilead SciencesRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Changhai HospitalCompleted
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis b
-
Zhongshan Hospital Xiamen UniversityUnknownHealthy | Chronic Hepatitis B InfectionChina
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
National Taiwan University HospitalChiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu Chi... and other collaboratorsRecruitingChronic Hepatitis b | Hepatitis B ReactivationTaiwan
-
Mahidol UniversityUnknownChronic Hepatitis B, HBsAg, Hepatitis B VaccineThailand
Clinical Trials on tenofovir disoproxil fumarate
-
National Institute of Allergy and Infectious Diseases...Microbicide Trials NetworkCompleted
-
National Institute of Allergy and Infectious Diseases...Microbicide Trials NetworkCompletedHIV InfectionsSouth Africa, Uganda, Zimbabwe
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHIV InfectionsUnited States, Puerto Rico
-
University of WashingtonBill and Melinda Gates FoundationCompletedHIV Infections | HIV-1 InfectionsKenya, Uganda
-
CONRADEastern Virginia Medical School; University of North Carolina; Agility Clinical...Completed
-
University of HawaiiGilead SciencesUnknown
-
Gilead SciencesCompletedChronic Hepatitis BUnited States, Canada, Spain, Singapore, Turkey, Germany, France, Taiwan, Greece, Italy, Poland
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis BChina
-
University of KwaZuluMedical Research Council, South Africa; Centre for the AIDS Programme of Research...Completed
-
University of ManitobaWorld Health Organization; DMSC; Ashodaya SamithiCompleted